Crossmark

Direct letters to relatives at risk of hereditary cancer—study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study)

Crossref DOI link: https://doi.org/10.1186/s13063-023-07829-5

Published Online: 2023-12-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hawranek, Carolina

Ehrencrona, Hans

Öfverholm, Anna

Hellquist, Barbro Numan

Rosén, Anna http://orcid.org/0000-0003-2441-2395
Funding

Funding for this research was provided by:

Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2018-00964)

Cancerfonden (2020-1107)

Vetenskapsrådet (2022-02226)

Umea University
License Information

Text and Data Mining valid from 2023-12-17

Version of Record valid from 2023-12-17
More Information

Article History

Received: 27 March 2023

Accepted: 22 November 2023

First Online: 17 December 2023

Declarations

:

: The protocol and amendments have been approved by the Swedish Ethical review authority.Dnr 2019-02647, approved 2019 June 19. Amendments: Dnr 2020-01176, approved 2020 May 18, Dnr 2021-00718, approved 2021 March 11, and Dnr 2021-05890, approved 2021 December 15.All patients participating in the study receive written and oral information before signing an informed consent to participate. The participant information and informed consent form, translated into English, are found in the InternalRef removed.

: N.A. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below